文献速递消化系统肿瘤乳腺癌妇科肿瘤

实体瘤中拓扑异构酶表达与扩增:24,262例患者分析

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
PubMed 文献 · Eur J Cancer · 2017-07-17

本研究分析24,262例多种实体瘤患者的TOPO1蛋白表达与TOP2A基因扩增,并检测HER2扩增。结果显示51%肿瘤TOPO1过表达,4%存在TOP2A扩增(胆囊癌及胃食管/食管癌超过10%),4903例同时评估TOP2A与HER2者中129例(2.6%)共扩增。

要点

  • 51%的肿瘤存在TOPO1蛋白过表达。
  • 4%的肿瘤存在TOP2A扩增,胆囊癌和胃食管/食管癌扩增率超过10%。
  • 4903例同时评估TOP2A与HER2,129例(2.6%)共扩增;TOP2A扩增的乳腺癌、卵巢癌、胃食管/食管癌和胰腺癌中HER2扩增率超过40%。

核心结论

  • TOPO1表达升高、TOP2A扩增及HER2共改变存在于多种恶性肿瘤中。
  • 这些观察对传统上不用于这些肿瘤类型的化疗敏感性的意义值得研究。

研究设计与样本

  • 分析24,262例多种癌症患者标本的TOPO1蛋白表达和TOP2A基因扩增,并检测HER2扩增。

主要发现

  • 51%的肿瘤存在TOPO1蛋白过表达。
  • 4%的肿瘤存在TOP2A扩增,胆囊肿瘤和胃食管/食管肿瘤的扩增率超过10%。
  • 共4903例标本同时评估TOP2A和HER2扩增,其中129例(2.6%)存在共扩增。
  • 在TOP2A扩增的乳腺癌、卵巢癌、胃食管/食管癌和胰腺癌患者中,HER2扩增率超过40%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Topoisomerase I (TOPO1) and topoisomerase IIα (TOP2A) are specific targets of multiple chemotherapy drugs. Increased expression of TOPO1 protein and amplification of the TOP2A gene have been associated with treatment response in colorectal and breast cancers, respectively. TOPO1 and TOP2A may be potential therapeutic targets in other malignancies as well. SUMMARY OF METHODS: We analysed TOPO1 protein expression and TOP2A gene amplification in patients (n = 24,262 specimens) with diverse cancers. Since HER2 and TOP2A co-amplification have been investigated for predictive value regarding anthracycline benefit, we analysed specimens for HER2 amplification as well. RESULTS: Overexpressed TOPO1 protein was present in 51% of the tumours. Four percent of the tumours had TOP2A amplification, with gallbladder tumours and gastroesophageal/oesophageal tumours having rates over 10%. Overall, 4903 specimens were assessed for both TOP2A and HER2 amplification; 129 (2.6%) had co-amplification. High rates (>40%) of HER2 amplification were seen in patients with TOP2A amplification in breast, ovarian, gastroesophageal/oesophageal and pancreatic cancer. CONCLUSION: Our data indicate that increased TOPO1 expression and TOP2A amplification, as well as HER2 co-alterations, are present in multiple malignancies. The implications of these observations regarding sensitivity to chemotherapy not traditionally administered to these tumour types merits investigation.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Heestand GM, Schwaederle M, Gatalica Z, et al. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients. Eur J Cancer. 2017. PMID: 28728050. doi:10.1016/j.ejca.2017.06.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。